1,470 research outputs found
Letter from L. N. McClellan to H. L. Hille Regarding Flood Protection, Land Purchase, Undated
This undated letter from Assistant Commissioner L. M. McClellan, assistant commissioner and chief enginerr of the United States (US) Bureau of Reclamation, to Colonel H. L. Hille, district engineer of the US Army Corps of Engineers, Garrison Distict, discusses flood protections and land purchase and rent.https://commons.und.edu/burdick-papers/1546/thumbnail.jp
Toward Abolitionist Remedies: Police (Non)Reform Litigation After the 2020 Uprisings
In the summer of 2020, across the country, Americans took to the street in protest of Mr. George Floyd’s murder and the police killings of countless other Black people. In too many cases, police responded to protesters with excessive force and the very brutality that had led people to protest police in the first place. In the wake of these horrific displays of force, over 40 lawsuits were filed nationwide that challenged police conduct at protests. Smith v. City of Philadelphia, one of the lawsuits brought on behalf of residents and protesters in Philadelphia, was unique because the tragic underlying facts in that case involved not only an attack on protesters, but also a broader attack on residents and bystanders who happened to be in the area. As one of the first police misconduct lawsuits brought in the midst of a national reckoning in the wake of George Floyd’s killing, the timing of the lawsuit also created the opportunity to reimagine the potential for litigation — not simply to seek police reform, but to further an abolitionist movement. In this article, we explore how impact litigators can pursue demands and visions for transformative and enduring change through what we term here as “abolitionist remedies.” In Part I, we provide historical context as to the long-standing pattern of police surveillance and excessive force against Black residents and activists in Philadelphia and in West Philadelphia specifically. In Part II, we provide an overview of the legal claims in the case, which included both excessive force and violations of the Equal Protection Clause. In Part III we discuss how we attempted to apply abolitionist principles to analyze which remedies to pursue in the context of the lawsuit. Finally, we offer a conclusion that recognizes some of the limitations of litigation for achieving non-reformist reforms
Mathematical Analysis and Simulations of the Neural Circuit for Locomotion in Lamprey
We analyze the dynamics of the neural circuit of the lamprey central pattern
generator (CPG). This analysis provides insights into how neural interactions
form oscillators and enable spontaneous oscillations in a network of damped
oscillators, which were not apparent in previous simulations or abstract phase
oscillator models. We also show how the different behaviour regimes
(characterized by phase and amplitude relationships between oscillators) of
forward/backward swimming, and turning, can be controlled using the neural
connection strengths and external inputs.Comment: 4 pages, accepted for publication in Physical Review Letter
Prozone Masks Elevated Sars-Cov-2 Antibody Level Measurements
We report a prozone effect in measurement of SARS-CoV-2 spike protein antibody levels from an antibody surveillance program. Briefly, the prozone effect occurs in immunoassays when excessively high antibody concentration disrupts the immune complex formation, resulting in a spuriously low reported result. Following participant inquiries, we observed anomalously low measurement of SARS-CoV-2 spike protein antibody levels using the Roche Elecsys® Anti-SARS-CoV-2 S immunoassay from participants in the Texas Coronavirus Antibody Research survey (Texas CARES), an ongoing prospective, longitudinal antibody surveillance program. In July, 2022, samples were collected from ten participants with anomalously low results for serial dilution studies, and a prozone effect was confirmed. From October, 2022 to March, 2023, serial dilution of samples detected 74 additional cases of prozone out of 1,720 participants\u27 samples. Prozone effect may affect clinical management of at-risk populations repeatedly exposed to SARS-CoV-2 spike protein through multiple immunizations or serial infections, making awareness and mitigation of this issue paramount
The impact of the abuse-deterrent reformulation of extended-release T OxyContin on prescription pain reliever misuse and heroin initiation
The introduction of abuse-deterrent OxyContin in 2010 was intended to reduce its misuse by making it more tamper resistant. However, some studies have suggested that this reformulation might have had unintended consequences, such as increases in heroin-related deaths. We used the 2005–2014 cross-sectional U.S. National Survey on Drug Use and Health to explore the impact of this reformulation on intermediate outcomes that precede heroin-related deaths for individuals with a history of OxyContin misuse. Our study sample consisted of adults who misused any prescription pain reliever prior to the reformulation of OxyContin (n = 81,400). Those who misused OxyContin prior to the reformulation were considered the exposed group and those who misused other prescription pain relievers prior to the reformulation were considered the unexposed group. We employed multivariate logistic regression under a difference-in-differences framework to examine the effect of the re- formulation on five dichotomous outcomes: prescription pain reliever misuse; prescription pain reliever use disorder; heroin use; heroin use disorder; and heroin initiation. We found a net reduction in the odds of pre- scription pain reliever misuse (OR:0.791, p \u3c 0.001) and heroin initiation (OR:0.422, p = 0.011) after the reformulation for the exposed group relative to the unexposed group. We found no statistically significant effects of the reformulation on prescription pain reliever use disorder (OR: 0.934, p = 0.524), heroin use (OR: 1.014p = 0.941), and heroin use disorder (OR: 1.063, p = 0.804). Thus, the reformulation of OxyContin appears to have reduced prescription pain reliever misuse without contributing to relatively greater new heroin use among those who misused OxyContin prior to the reformulation
Shadowing in the nuclear photoabsorption above the resonance region
A model based on the hadronic fluctuations of the real photon is developed to
describe the total photonucleon and photonuclear cross sections in the energy
region above the nucleon resonances. The hadronic spectral function of the
photon is derived including the finite width of vector-meson resonances and the
quark-antiquark continuum. The shadowing effect is evaluated considering the
effective interaction of the hadronic component with the bound nucleons within
a Glauber-Gribov multiple scattering theory. The low energy onset of the
shadowing effect is interpreted as a possible signature of a modification of
the hadronic spectral function in the nuclear medium. A decrease of the
-meson mass in nuclei is suggested for a better explanation of the
experimental data.Comment: 8 pages, 7 figure
The equation of state of solid nickel aluminide
The pressure-volume-temperature equation of state of the intermetallic
compound NiAl was calculated theoretically, and compared with experimental
measurements. Electron ground states were calculated for NiAl in the CsCl
structure, using density functional theory, and were used to predict the cold
compression curve and the density of phonon states. The Rose form of
compression curve was found to reproduce the ab initio calculations well in
compression but exhibited significant deviations in expansion. A
thermodynamically-complete equation of state was constructed for NiAl. Shock
waves were induced in crystals of NiAl by the impact of laser-launched Cu
flyers and by launching NiAl flyers into transparent windows of known
properties. The TRIDENT laser was used to accelerate the flyers to speeds
between 100 and 600m/s. Point and line-imaging laser Doppler velocimetry was
used to measure the acceleration of the flyer and the surface velocity history
of the target. The velocity histories were used to deduce the stress state, and
hence states on the principal Hugoniot and the flow stress. Flyers and targets
were recovered from most experiments. The effect of elasticity and plastic flow
in the sample and window was assessed. The ambient isotherm reproduced static
compression data very well, and the predicted Hugoniot was consistent with
shock compression data
An aggregating U-Test for a genetic association study of quantitative traits
We propose a novel aggregating U-test for gene-based association analysis. The method considers both rare and common variants. It adaptively searches for potential disease-susceptibility rare variants and collapses them into a single “supervariant.” A forward U-test is then used to assess the joint association of the supervariant and other common variants with quantitative traits. Using 200 simulated replicates from the Genetic Analysis Workshop 17 mini-exome data, we compare the performance of the proposed method with that of a commonly used approach, QuTie. We find that our method has an equivalent or greater power than QuTie to detect nine genes that influence the quantitative trait Q1. This new approach provides a powerful tool for detecting both common and rare variants associated with quantitative traits
The Opportunities and challenges in development of a multi-agency program to monitor and assess reef fish populations in the Florida Keys coral reef ecosystem
Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
<p>Abstract</p> <p>Background</p> <p>Anaemia is a common complication of chronic kidney disease and prevalence increases with declining renal function. Renal anaemia has significant implications for the well-being and quality of life of patients and impacts on morbidity and mortality. Anaemia can be well managed by therapy with erythropoiesis-stimulating agents (ESAs). Previous clinical trials have shown that the only human cell-line-derived ESA, epoetin delta, is well tolerated and effective in maintaining haemoglobin levels in anaemic patients with chronic kidney disease. The half-life of epoetin delta suggests that administration of this agent is feasible once weekly and once every two weeks. We report on the design and rationale of a trial to compare once weekly <it>vs</it>. twice weekly, and once weekly <it>vs</it>. once every two weeks dosing of epoetin delta.</p> <p>Design and methods</p> <p>This is a randomized, open-label, multicentre trial. Patients aged 18 years or above with chronic kidney disease (Stages 3–5) are eligible to enter this trial. Two groups of patients form the trial population, those naïve to ESA therapy and those previously stable on ESA therapy. There are two primary objectives of this trial: 1) to demonstrate non-inferiority between twice weekly and once weekly dosing of epoetin delta in previously naïve patients (assessed by haemoglobin at Week 24); 2) to demonstrate non-inferiority between once weekly and once every two weeks dosing in previously stable patients (assessed by average haemoglobin over Weeks 16–24). Among the secondary analyses will be assessments of haematocrit, number(%) of patients meeting predefined targets for haemoglobin and haematocrit levels, and comparisons of average dose. All patients will receive study medication for 24 weeks and dose will be adjusted according to a predefined algorithm to achieve and maintain haemoglobin ≥ 11 g/dL. All patients completing this trial are eligible to enter a 2-year follow-up study to enable monitoring of emergent adverse events, anti-erythropoietin antibody responses, maintenance of efficacy and changes in diabetic retinopathy status.</p> <p>Discussion</p> <p>To our knowledge, this trial is the first to randomize ESA-naïve patients to different dosing regimens of the same ESA. Data generated will help in guiding the most appropriate dosing frequency for epoetin delta, particularly in those patients new to epoetin delta therapy.</p> <p>Trial registration</p> <p><b>ClinicalTrials.gov: </b>NCT00450333</p
- …